摘要
目的探讨非那雄胺联合小剂量骨化三醇对前列腺增生患者血钙的影响。方法 100例前列腺增生患者,按随机数字表法分为试验组和对照组各50例,试验组口服非那雄胺(5 mg,1次/天)联合骨化三醇胶丸(0.25μg,隔天1次),对照组服用安慰剂联合非那雄胺(0.25μg,隔天1次)。两组均治疗6个月,每两周检测患者各项血清生化指标、血钙和雄激素水平。结果两组患者血钙、雄激素比较差异均无统计学意义(P>0.05),试验组在骨骼特异性碱性磷酸酶和骨密度方面有一定程度改善,但与对照组比较差异无统计学意义(P>0.05)。结论服用非那雄胺联合小剂量骨化三醇不会增加患者得高钙血症的风险。
Objective To investigate curative effects and clinical safety for fiuasteride combined with low doses of calcitriol in the treatment of prostate hyperplasia patients with hypercaleemia. Methods One hundred patients with benign prostatic hyperplasia were randomly divided into two groups ,50 cases in each. Patients in experimental group were treated with finasteride（5 mg daily） and calcitriol capsules（0.25 p,g,once every other day）. Patients in control group were treated with the placebo and the same dose of finasteride as experimental group. Results After 6 months treatment, no significant differences in levels of serum calcium and androgen were found between two groups. Patients in experimental group showed a certain degree of improvement in bone-specific alkaline phos-phatase and bone mineral density. However, the improvement was not statistically different from the control group（ P 〉 0. 05 ）. Conclusions Finasterid combined with low doses of calcitriol did not increase the risk of hypercalcemia in patients with prostate hyperplasia.
出处
《实用医院临床杂志》
2012年第5期99-101,共3页
Practical Journal of Clinical Medicine
关键词
非那雄胺
骨化三醇
前列腺增生
血钙
Finasteride
Calcitriol
Prostatic hyperplasia
Hypercalcemia
